Drug profile · INN
plerixafor
PLERIXAFOR ARX
plerixafor (PLERIXAFOR ARX) is a c-x-c chemokine receptor type 4 partial agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — plerixafor
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L03)
- Route
- SUBCUTANEOUS
- Patents
- 20
- Programs
- 15
- Data quality
- 0.89
Quick answer
plerixafor (PLERIXAFOR ARX) is a c-x-c chemokine receptor type 4 partial agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
C-X-C chemokine receptor type 4 partial agonist
Primary target: C-X-C chemokine receptor type 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12318427
Methods and compositions for modulation of tau proteins
granted -
US 12139517
Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
granted -
US 12043650
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
granted -
US 11981967
Engineering AAV
granted -
US 11859190
Methods and compositions for regulation of transgene expression
granted -
US 11845965
Regulation of gene expression using engineered nucleases
granted -
US 11827900
Engineered target specific nucleases
granted -
US 11793888
Methods and compositions for engineering immunity
granted -
US 11723952
Methods and compositions for treating Huntington's Disease
granted -
US 11690921
Delivery of target specific nucleases
granted -
US 11661611
Genetic modification of cytokine inducible SH2-containing protein (CISH) gene
granted -
US 11661612
DNA-binding proteins and uses thereof
granted -
US 11655275
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
granted -
US 11648267
Methods and compositions for gene inactivation
granted -
US 11639504
Methods and compositions for regulation of transgene expression
granted -
US 11634463
Methods and compositions for treating hemophilia
granted -
US 11504389
Tau modulators and methods and compositions for delivery thereof
granted -
US 11452782
Liver-specific constructs factor VIII expression cassettes and methods of use thereof
granted -
US 11401512
Engineered target specific nucleases
granted -
US 11235026
Methods and compositions for modulating PD1
granted
Frequently asked questions
What is plerixafor?
plerixafor (PLERIXAFOR ARX) is a c-x-c chemokine receptor type 4 partial agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for plerixafor?
PLERIXAFOR ARX is a marketed brand name for plerixafor. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of plerixafor?
plerixafor has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.